Chronic T-Cell Leukemia (CTCL)
Symptoms, Doctors, Treatments, Advances & More

Chronic T-Cell Leukemia (CTCL) Overview

Save information for later
Sign Up

Learn About Chronic T-Cell Leukemia (CTCL)

View Main Condition: Leukemia

What is the definition of Chronic T-Cell Leukemia (CTCL)?
Chronic T-cell leukemia is a type of chronic lymphocytic leukemia (CLL), or cancer of the blood and bone marrow that mainly affects adults. In chronic T-cell leukemia, there is an overproduction of T lymphocytes, which are white blood cells that fight infection. Chronic T-cell leukemia has four subtypes: 1) large granular lymphocytic leukemia (LGLL), which is slow-growing; 2) T-cell prolymphocytic leukemia (T-PLL), which is aggressive, or fast-growing; 3) adult T-cell leukemia/lymphoma (ATLL); and 4) Sezary syndrome, which is a type of T-cell lymphoma that only occurs on the skin.
What are the symptoms of Chronic T-Cell Leukemia (CTCL)?
Individuals with early chronic T-cell leukemia may not have any symptoms. Symptoms of intermediate and advanced stage chronic T-cell leukemia depend on the type and may include painless, enlarged lymph nodes; fatigue; fever; pain in the upper left region of the abdomen; enlarged spleen; easy bruising or bleeding; pinpoint, dark red spots under the skin (petechiae); rash; frequent urination and/or constipation; night sweats; weight loss; abdominal pain or fullness; and frequent infections.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Chronic T-Cell Leukemia (CTCL)?
Treatment for chronic T-cell leukemia depends on the type and stage. Early stage chronic T-cell leukemia may not need treatment and may involve watchful waiting. Treatments for intermediate and advanced stages chronic T-cell leukemia may include targeted therapy, chemotherapy, radiation therapy, immunotherapy, splenectomy, and bone marrow or peripheral stem cell transplant.
Who are the top Chronic T-Cell Leukemia (CTCL) Local Doctors?
Distinguished in Chronic T-Cell Leukemia (CTCL)
Dr. Adam P. Siegel
Hematology | Oncology
Distinguished in Chronic T-Cell Leukemia (CTCL)
Dr. Adam P. Siegel
Hematology | Oncology

Vince Lombardi Cancer Clinic

36500 Aurora Dr, 
Summit, WI 
262-434-8800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Adam Siegel is a Hematologist and an Oncologist practicing medicine in Summit, Wisconsin. Dr. Siegel is rated as a Distinguished provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). He is also highly rated in 46 other conditions, according to our data. His clinical expertise encompasses Adult T-Cell Leukemia, Chronic T-Cell Leukemia (CTCL), Angiosarcoma, and Inflammatory Breast Cancer. Dr. Siegel is board certified in American Board Of Internal Medicine, Hematology.

Elite in Chronic T-Cell Leukemia (CTCL)
Michael J. Hallek
Elite in Chronic T-Cell Leukemia (CTCL)
Michael J. Hallek
Joseph Stelzmann Str. 26, 
Koeln, NW, DE 

Michael Hallek practices practicing medicine in Koeln, Germany. Mr. Hallek is rated as an Elite expert by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, Bone Marrow Transplant, and Bone Graft.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Chronic T-Cell Leukemia (CTCL)
Stephan Stilgenbauer
Elite in Chronic T-Cell Leukemia (CTCL)
Stephan Stilgenbauer
Albert Einstein Allee 23, 
Ulm, BW, DE 

Stephan Stilgenbauer practices practicing medicine in Ulm, Germany. Mr. Stilgenbauer is rated as an Elite expert by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Bone Marrow Transplant, and Bone Graft.

View All Doctors
What are the latest Chronic T-Cell Leukemia (CTCL) Clinical Trials?
Phase II Study of Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant in T-Cell Lymphoma
Phase II Study of Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant in T-Cell Lymphoma
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Procedure, Drug
Study Phase: Phase 2

Summary: This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The graft is the donor blood cells that patients get during the transplant. The host is the person receiving...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase I Multicenter Study of Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell Lymphomas
Phase I Multicenter Study of Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell Lymphomas
Who is this study for: Patients with Lymphomas
Enrollment Status: Recruiting
Publish Date: April 09, 2026
Intervention Type: Drug
Study Drugs: Ruxolitinib, Duvelisib
Study Phase: Phase 1

Summary: This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma. This study has three parts: dose escalation (Part 1), dose expansion (Part 2), and TFH/T-PLL cohort expansion (Part 3).

View All Clinical Trials